Skip to main content

Table 3 Previous use of osteoporosis and analgesic medications

From: Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS)

CharacteristicColombia
(N = 277)
Brazil
(N = 130)
Mexico
(N = 83)
Argentina
(N = 56)
All Patients Latin America Subregion (N = 546)
Past use of osteoporosis medicationa, n (%)181 (65.3%)96 (73.8%)58 (69.9%)52 (92.9%)387 (70.9%)
Number of previous osteoporosis medications, n (%)
096 (34.7%)34 (26.2%)25 (30.1%)4 (7.1%)159 (29.1%)
195 (34.3%)29 (22.3%)12 (14.5%)10 (17.9%)146 (26.7%)
260 (21.7%)39 (30.0%)14 (16.9%)23 (41.1%)136 (24.9%)
320 (7.2%)24 (18.5%)11 (13.3%)17 (30.4%)72 (13.2%)
45 (1.8%)4 (3.1%)17 (20.5%)1 (1.8%)27 (4.9%)
5 or more1 (0.4%)0 (0.0%)4 (4.8%)1 (1.8%)6 (1.1%)
Previous pharmacotherapy for osteoporosisb, n (%)
Alendronate31 (11.2%)37 (28.5%)20 (24.1%)6 (10.7%)94 (17.2%)
Ibandronate23 (8.3%)3 (2.3%)9 (10.8%)11 (19.6%)46 (8.4%)
Risedronate4 (1.4%)10 (7.7%)4 (4.8%)6 (10.7%)24 (4.4%)
Zoledronate21 (7.6%)6 (4.6%)23 (27.7%)1 (1.8%)51 (9.3%)
Other bisphosphonates1 (0.4%)1 (0.8%)1 (1.2%)2 (3.6%)5 (0.9%)
Any one or more bisphosphonates73 (26.4%)49 (37.7%)46 (55.4%)22 (39.3%)190 (34.8%)
Calcitonin3 (1.1%)3 (2.3%)1 (1.2%)0 (0.0%)7 (1.3%)
Calcium only119 (43.0%)65 (50.0%)34 (41.0%)39 (69.6%)257 (47.1%)
Denosumab13 (4.7%)0 (0.0%)8 (9.6%)5 (8.9%)26 (4.8%)
Raloxifene0 (0.0%)1 (0.8%)3 (3.6%)0 (0.0%)4 (0.7%)
Strontium ranelate2 (0.7%)4 (3.1%)1 (1.2%)2 (3.6%)9 (1.6%)
Vitamin D only82 (29.6%)61 (46.9%)31 (37.3%)45 (80.4%)219 (40.1%)
Use of ≥1 back pain medication over the past 24 h, n (%)94 (33.9%)23 (17.7%)24 (28.9%)26 (46.4%)167 (30.6%)
Specific back pain medications, n (%)
NSAIDs11 (4.0%)6 (4.6%)19 (22.9%)14 (25.0%)50 (9.2%)
Paracetamol66 (23.8%)5 (3.8%)10 (12.0%)8 (14.3%)89 (16.3%)
Opioids22 (7.9%)2 (1.5%)0 (0.0%)4 (7.1%)28 (5.1%)
Paracetamol and opioid combination2 (0.7%)0 (0.0%)0 (0.0%)0 (0.0%)2 (0.4%)
  1. N = total number of patients available; n = number of patients with valid (non-missing or unknown) values; NSAIDs = nonsteroidal anti-inflammatory drugs
  2. aThis includes ongoing medications as well as those stopped before baseline
  3. bPrior osteoporosis medications taken by > 0.5% of all patients in the overall Latin American subregional cohort
  4. Note: Percentages are calculated using n, the number of valid (not missing or unknown) responses for each item